Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children

2008/09/17 by Terry Nolan, Peter C. Richmond, Peter Richmond +16 · 26 citations
Medicine · #Influenza Virus Research Studies #Virology and Viral Diseases #Respiratory viral infections research

paper · doi:10.1016/j.vaccine.2008.08.046

Cited by

• A live attenuated NS1-deficient vaccine candidate for cattle-origin influenza A (H5N1) clade 2.3.4.4.b viruses
• A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. [europepmc]
• Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. [europepmc]
• Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. [europepmc]
• Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. [europepmc]
• Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. [europepmc]
• A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus. [europepmc]
• Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. [europepmc]
• Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. [europepmc]
• Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. [europepmc]
• An overview of the highly pathogenic H5N1 influenza virus. [europepmc]
• H5N1 vaccines in humans. [europepmc]
• Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. [europepmc]
• Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study. [europepmc]
• AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial. [europepmc]
• Assaying the Potency of Influenza Vaccines. [europepmc]
• Refining the approach to vaccines against influenza A viruses with pandemic potential. [europepmc]
• Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost. [europepmc]
• Pandemic Influenza Vaccines: What did We Learn from the 2009 Pandemic and are We Better Prepared Now? [europepmc]
• Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. [europepmc]
• Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. [europepmc]
• Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice. [europepmc]
• An Advax-Adjuvanted Inactivated Cell-Culture Derived Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-Flavivirus Antibodies, Robust Cellular Immunity and Provides Single Dose Protection. [europepmc]
• Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection. [europepmc]
• Repeated influenza vaccination induces similar immune protection as first-time vaccination but with differing immune responses. [europepmc]
• Influenza virus immune imprinting dictates the clinical outcomes in ferrets challenged with highly pathogenic avian influenza virus H5N1. [europepmc]